Clinical trial
Creatine Safety and Tolerability in Premanifest HD: PRECREST
NCT00592995 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Creatine Safety and Tolerability in Premanifest HD: PRECREST
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- September 30, 2012
- Enrollment
- 64 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.